This product is free for those who attended FNCE® 2018.
In 2018, President Trump signed into law the "Right to Try," which promised to allow patients who had no other treatment options available to be able to access investigational, experimental medicines. But this is only the latest of several pathways by which patients can seek (non-guaranteed) access to investigational treatments.
In this session, led by an expert in access to investigational medical products, you will learn about the three primary routes by which patients with no other options may access experimental, unapproved medicines. The pros and cons of each of these routes will be reviewed and what members of the health care team ought to be aware of for each will be discussed.
The session will be framed from the perspective of what information and issues healthcare providers should be aware of when dealing with patients who are taking, or seeking, access to investigational, unapproved medicines. The presentation will draw upon case studies and will include ample opportunity for questions. An oncology dietitian will assist in discussing the impact of seeking to access experimental medicines via the "Right to Try" pathway could impact nutrition care.
CPE Level: 2
Learning Codes: 1050, 6010, 7050
- Explain the three routes by which patients may access investigational, experimental medicines.
- Identify the risks and benefits of each of these routes.
- Utilize this knowledge to educate RDN non-RDN colleagues who have interactions with patients who are using or who may wish to use unapproved, investigational medicines as treatment.